Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Social security beneficiaries affiliated to the LA RAZA UMAE HECMN~* Adults over 18 years old~* Male or female subjects~* Diagnosed with scleroderma (2013 ACR-EULAR)~* Score above the 25th percentile in NIH-PROMIS questionnaire~* Positive result (\> 10 ppm) in the hydrogen breath test~* Normal leukocyte and lymphocyte profiles~* Patients who accept to participate in the study by signing the informed consent form~Exclusion Criteria:~* Gastrointestinal diseases already diagnosed and not associated to systemic sclerosis~* Comorbidities associated to visceral diseases (diabetes, amyloidosis or other infiltrative diseases)~* Currently under biological treatment (or history of biological treatment in the last year) with cyclophosphamide and \> 10 mg prednisone or equivalent~* Allergy or contra-indications to metronidazole or to Saccharomyces boulardii,~* Central venous catheter carriers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Saccaromyces boulardii oral tablet (Type: ACTIVE_COMPARATOR): Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
- Metronidazole plus S. boulardii (Type: ACTIVE_COMPARATOR): Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months.
- Metronidazole (Type: ACTIVE_COMPARATOR): Metronidazole 500 mg b.i.d during 1 week, plus Saccharomyces boulardii 200 mg b.i.d. during 1 week, follow for only Saccharomyces 200 mg b.i.d. for one another week, 2-week rest period and then this regimen is repeated for two consecutive months.

Based on this trial design, predict the completion outcome and termination type (if applicable).